Gut microbiota in PCOS: key microbial changes, potential mechanisms and clinical applications.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and therapeutic targets without primary human data or systematic review methodology.
PubMed 42249447 · doi:10.1186/s12967-026-08352-2
What was done
Narrative review summarizing published literature on gut microbiota alterations in polycystic ovary syndrome (PCOS). The authors evaluated reported taxonomic shifts, functional metabolic impairments including short-chain fatty acid production, bidirectional metabolic-immune-endocrine mechanisms, and potential microbiota-targeted interventions such as dietary strategies, probiotics, prebiotics, and synbiotics.
What was found
The abstract reports no quantitative values, sample sizes, or effect estimates. It describes qualitative findings from the literature: individuals with PCOS exhibit microbial dysbiosis, including reduced Lachnospira and lower short-chain fatty acid production, which correlate with exacerbated insulin resistance, chronic inflammation, and hyperandrogenism.
Why it matters
Synthesizes proposed mechanistic links between gut microbial dysbiosis and PCOS pathophysiology, highlighting potential targets for future dietary and microbiome-based interventions.
Limits
As a narrative review, it presents no original empirical data, quantitative synthesis, or meta-analysis. The summarized body of evidence is constrained by study heterogeneity, undefined clinical effect sizes, and unresolved mechanistic causality.
Cited by
- supports The gut microbiome is made up of trillions of microorganisms that line the digestive tract and affect immune status, metabolic health, and hormone regulation.